Prognostic performance of copeptin among patients with acute decompensated heart failure
Authors:
- Caglar OzmenCOCaglar Ozmen
- Onur Sinan DeveciODOnur Sinan Deveci
- Omer TepeOTOmer Tepe
- Cuma YesildasCYCuma Yesildas
- İlker ÜnalIÜİlker Ünal
- İbrahim YıldızIYİbrahim Yıldız
- Rabia Eker AkıllıRARabia Eker Akıllı
- Ali DenizADAli Deniz
- Mesut DemirMDMesut Demir
- Mehmet KanadaşıMKMehmet Kanadaşı
- Ayhan UsalAUAyhan Usal
- 15 July 2020
- journal article
- research article
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 76 (8) , 842-851
Abstract
Background In heart failure (HF), various biomarkers have been established for prognosis. However, little is known about the relevance of copeptin measurements to HF. This study aimed to explore the prognostic value of copeptin for predicting cardiovascular (CV) death or HF-related re-hospitalisation in patients with acute decompensated HF. Materials and Methods We prospectively enrolled 155 consecutive patients with acute signs and symptoms of HF. Plasma copeptin and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were measured at admission. Patients were monitored for 90 days regarding the composite endpoint of CV death or acute HF-related re-hospitalisation. Results Of the 155 patients enrolled, 40 reached the endpoint, and 115 were in a stable condition during follow-up. Patients who reached an adverse endpoint showed higher NT-proBNP and copeptin levels compared to patients in stable condition. Receiver operating characteristic curve analysis revealed that the area under curve of copeptin 0.844 (95% CI, 0.753-0.935) was superior to that of NT-proBNP 0.809 (95% CI, 0.729-0.890) for the prediction of adverse events within 90 days. Meanwhile, compared to the group with lower copeptin levels (= 34 pmol/L) were at a 10.672-times higher risk of CV death or acute HF-related re-hospitalisation. Multivariate Cox proportional hazards regression analysis revealed that increased copeptin level was a significantly independent predictor of adverse events (risk ratio, 1.051; 95% CI, 1.020-1.083;p < 0.001). Conclusion Copeptin was found to be a strong, novel marker for predicting CV death or HF-related re-hospitalisation in patients with acute decompensated HF.Keywords
This publication has 38 references indexed in Scilit:
- Copeptin and cardiovascular disease: A review of a novel neurohormoneInternational Journal of Cardiology, 2013
- Tolvaptan Improves Left Ventricular Dysfunction after Myocardial Infarction in RatsCirculation: Heart Failure, 2012
- ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012European Journal of Heart Failure, 2012
- Short‐term Mortality Risk in Emergency Department Acute Heart FailureAcademic Emergency Medicine, 2011
- Increased 90-Day Mortality in Patients With Acute Heart Failure With Elevated CopeptinCirculation: Heart Failure, 2011
- Prognostic Value of CopeptinStroke, 2010
- C-Terminal Provasopressin (Copeptin) is Associated With Left Ventricular Dysfunction, Remodeling, and Clinical Heart Failure in Survivors of Myocardial InfarctionJournal of Cardiac Failure, 2008
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)European Heart Journal, 2008
- Copeptin: clinical use of a new biomarkerTrends in Endocrinology & Metabolism, 2008
- Management of Vasodilatory ShockDrugs, 2003